Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

5,858 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Pharmacology of imatinib (STI571).
Buchdunger E, O'Reilly T, Wood J. Buchdunger E, et al. Among authors: wood j. Eur J Cancer. 2002 Sep;38 Suppl 5:S28-36. doi: 10.1016/s0959-8049(02)80600-1. Eur J Cancer. 2002. PMID: 12528770 Review.
Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Wood JM. Wood JM. Medicina (B Aires). 2000;60 Suppl 2:41-7. Medicina (B Aires). 2000. PMID: 11188930
Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors.
Schlaeppi JM, Wood JM. Schlaeppi JM, et al. Among authors: wood jm. Cancer Metastasis Rev. 1999;18(4):473-81. doi: 10.1023/a:1006358220123. Cancer Metastasis Rev. 1999. PMID: 10855790 Review.
PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O'Reilly T, Persohn E, Rösel J, Schnell C, Stover D, Theuer A, Towbin H, Wenger F, Woods-Cook K, Menrad A, Siemeister G, Schirner M, Thierauch KH, Schneider MR, Drevs J, Martiny-Baron G, Totzke F. Wood JM, et al. Cancer Res. 2000 Apr 15;60(8):2178-89. Cancer Res. 2000. PMID: 10786682
Differential effects of the vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 on tumor angiogenesis and tumor lymphangiogenesis.
Schomber T, Zumsteg A, Strittmatter K, Crnic I, Antoniadis H, Littlewood-Evans A, Wood J, Christofori G. Schomber T, et al. Among authors: wood j. Mol Cancer Ther. 2009 Jan;8(1):55-63. doi: 10.1158/1535-7163.MCT-08-0679. Mol Cancer Ther. 2009. PMID: 19139113
The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment.
Lin B, Podar K, Gupta D, Tai YT, Li S, Weller E, Hideshima T, Lentzsch S, Davies F, Li C, Weisberg E, Schlossman RL, Richardson PG, Griffin JD, Wood J, Munshi NC, Anderson KC. Lin B, et al. Among authors: wood j. Cancer Res. 2002 Sep 1;62(17):5019-26. Cancer Res. 2002. PMID: 12208756
PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging.
Drevs J, Müller-Driver R, Wittig C, Fuxius S, Esser N, Hugenschmidt H, Konerding MA, Allegrini PR, Wood J, Hennig J, Unger C, Marmé D. Drevs J, et al. Among authors: wood j. Cancer Res. 2002 Jul 15;62(14):4015-22. Cancer Res. 2002. PMID: 12124335
The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade.
Sini P, Wyder L, Schnell C, O'Reilly T, Littlewood A, Brandt R, Hynes NE, Wood J. Sini P, et al. Among authors: wood j. Clin Cancer Res. 2005 Jun 15;11(12):4521-32. doi: 10.1158/1078-0432.CCR-04-1954. Clin Cancer Res. 2005. PMID: 15958638
PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo.
Rudin M, McSheehy PM, Allegrini PR, Rausch M, Baumann D, Becquet M, Brecht K, Brueggen J, Ferretti S, Schaeffer F, Schnell C, Wood J. Rudin M, et al. Among authors: wood j. NMR Biomed. 2005 Aug;18(5):308-21. doi: 10.1002/nbm.961. NMR Biomed. 2005. PMID: 15918178
AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G. Traxler P, et al. Among authors: wood j. Cancer Res. 2004 Jul 15;64(14):4931-41. doi: 10.1158/0008-5472.CAN-03-3681. Cancer Res. 2004. PMID: 15256466
5,858 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback